With Two COVID-19 Vaccines Likely on the Way, Distribution Becomes Key Issue

With Two COVID-19 Vaccines Likely on the Way, Distribution Becomes Key Issue

On November 12, the New York Times took a look at the distribution planning for the Pfizer and BioNTech vaccine product known as BNT162b2. The companies just submitted filed for an emergency use authorization (EUA) based on a 95% effectivity rate.  Now that the vaccine shows exciting promise, public health officials face down a new challenge: rapidly manufacturing vaccine and getting millions of doses to hospitals, clinics, and pharmacies. If, as expected, FDA grants an emergency use authorization (EUA) for this vaccine, in theory millions of Americans could be vaccinated by the end of the year leveraging months of planning. “I am very confident. I live and breathe this,” Tanya Alcorn, the Pfizer executive who oversees the vaccine supply, opined. “We have developed a system that does not waste any precious vaccine.” The effort depends on collaboration among companies, federal and stage agencies, and on-the-ground health care workers. Prior to shipping vaccine, both federal and state governments must advise where to send how many does. McKesson, who is a major medical supply firm contracted with the federal vaccine effort called Operation Warp Speed (OWS), will be tasked with ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee